ReviewCureus2026
Early Allergen Introduction in Delaware: A Model to Address Healthcare Disparities and Population Healthcare Costs.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Food allergies introduce substantial clinical risks to patients and long-term economic burdens for families and health systems. In the past two decades, pediatric allergen introduction guidelines have come full circle, promoting the introduction of allergenic foods during infancy to support immune tolerance and reduce the likelihood of developing lifelong allergies. However, the translation of this clinical evidence into real-world policy and practice remains unevenly distributed; adoption barriers disproportionately affect families facing financial constraints, limited access to consistent guidance, or heightened fear of adverse reactions. If legislated as a preventive measure, early allergen introductions could aim to improve health equity, narrow socioeconomic and racial disparities in community adoption, and reduce downstream expenditures associated with chronic management and emergency care. This narrative review and policy commentary reviews the strong clinical and public policy rationale for early allergen introduction, outlines the equity implications of statewide coverage mandates, and discusses the passage of an innovative policy mandating statewide coverage in Delaware. Comparative emerging efforts in other states and Medicaid programs that could represent subsequent steps in a broader shift toward population-level prevention are also discussed. Ongoing evaluation of patient adherence, food allergy incidence rates, and the policy's cost-effectiveness will be essential to determine whether Delaware's model can sustainably reduce new food allergy cases and to inform policy nationwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.